Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Curcumin Pill

Phase 1Small molecule

SShahid Beheshti University of Medical Sciences

Curcumin Pill is one of 26 small molecule programs targeting Hematoma. It is currently in Phase 1.

1

Indications

2

Total Trials

0

Active Trials

25

Competitors

Pipeline

Status by Indication[3][1]

Indication

HematomaActive, not recruiting

HematomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Hematoma

#DrugCompanyPhaseTrials

Cyklokapron

Keppra

Eliquis

Bristol-Myers Squibb

Toradol

JJavelin Pharmaceuticals

Xylocaine

MMEDRx USA, Inc.

Marcaine

Prometrium

Topamax

Xarelto

Medrol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dialysis Patients1 trial

Evaluation of Curcumin's Effect on Inflammation in Hemodialysis Patients

Completed·SShahid Beheshti University of Medical Sciences·N/A·NCT03144882·71 enrolled

Hematoma1 trial

Curcumin/Turmeric as a Treatment for Patients With Subdural Hematomas Recurrence

Withdrawn·UUniversity of New Mexico·Phase 1·NCT03845322

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Curcumin Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Curcumin Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Curcumin Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shahid Beheshti University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShahid Beheshti University of Medical Sciences

Related News